Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine

Transplant Proc. 1999 Sep;31(6):2522-3. doi: 10.1016/s0041-1345(99)00445-5.

Authors

J A Rodríguez¹, M G Crespo-Leiro, M J Paniagua, J J Cuenca, L F Hermida, A Juffé, A Castro-Beiras

Affiliation

¹ Heart Transplant Program, Hospital Juan Canalejo, La Coruña, Spain.

PMID: 10500698
DOI: 10.1016/s0041-1345(99)00445-5

No abstract available

MeSH terms

Adult
Aged
Cholesterol / blood
Cyclosporine / adverse effects
Cyclosporine / therapeutic use*
Female
Heart Transplantation* / immunology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / drug therapy
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Male
Middle Aged
Postoperative Complications
Retrospective Studies
Rhabdomyolysis / chemically induced*
Rhabdomyolysis / epidemiology

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Immunosuppressive Agents
Cyclosporine
Cholesterol